Sager Jennifer E, Yu Jingjing, Ragueneau-Majlessi Isabelle, Isoherranen Nina
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington.
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington
Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21.
Modeling and simulation of drug disposition has emerged as an important tool in drug development, clinical study design and regulatory review, and the number of physiologically based pharmacokinetic (PBPK) modeling related publications and regulatory submissions have risen dramatically in recent years. However, the extent of use of PBPK modeling by researchers, and the public availability of models has not been systematically evaluated. This review evaluates PBPK-related publications to 1) identify the common applications of PBPK modeling; 2) determine ways in which models are developed; 3) establish how model quality is assessed; and 4) provide a list of publically available PBPK models for sensitive P450 and transporter substrates as well as selective inhibitors and inducers. PubMed searches were conducted using the terms "PBPK" and "physiologically based pharmacokinetic model" to collect published models. Only papers on PBPK modeling of pharmaceutical agents in humans published in English between 2008 and May 2015 were reviewed. A total of 366 PBPK-related articles met the search criteria, with the number of articles published per year rising steadily. Published models were most commonly used for drug-drug interaction predictions (28%), followed by interindividual variability and general clinical pharmacokinetic predictions (23%), formulation or absorption modeling (12%), and predicting age-related changes in pharmacokinetics and disposition (10%). In total, 106 models of sensitive substrates, inhibitors, and inducers were identified. An in-depth analysis of the model development and verification revealed a lack of consistency in model development and quality assessment practices, demonstrating a need for development of best-practice guidelines.
药物处置的建模与模拟已成为药物研发、临床研究设计和监管审评中的一项重要工具,近年来基于生理的药代动力学(PBPK)建模相关的出版物数量和监管申报数量急剧增加。然而,研究人员对PBPK建模的使用程度以及模型的公开可用性尚未得到系统评估。本综述评估了与PBPK相关的出版物,以:1)确定PBPK建模的常见应用;2)确定模型的开发方式;3)确定评估模型质量的方法;4)提供一份公开可用的针对敏感P450和转运体底物以及选择性抑制剂和诱导剂的PBPK模型清单。使用术语“PBPK”和“基于生理的药代动力学模型”在PubMed上进行检索,以收集已发表的模型。仅对2008年至2015年5月期间以英文发表的关于人体药物PBPK建模的论文进行了综述。共有366篇与PBPK相关的文章符合检索标准,每年发表的文章数量稳步上升。已发表的模型最常用于药物相互作用预测(28%),其次是个体间变异性和一般临床药代动力学预测(23%)、制剂或吸收建模(12%)以及预测药代动力学和处置中与年龄相关的变化(10%)。总共识别出106个敏感底物、抑制剂和诱导剂的模型。对模型开发和验证的深入分析表明,模型开发和质量评估实践缺乏一致性,这表明需要制定最佳实践指南。